Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us ![]()
About
PEGS Boston SummitPEGS Boston Summit
Not Confirmed
Not Confirmed
11 May-15 November, 2026
CPhI North AmericaCPhI North America
Not Confirmed
Not Confirmed
02-04 June, 2026
Not Confirmed
Not Confirmed
03-05 June, 2026
List your booth number for exhibitions, ask us
CONTACT DETAILS




Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
PEGS Boston SummitPEGS Boston Summit
Industry Trade Show
Not Confirmed
11 May-15 November, 2026
CPhI North AmericaCPhI North America
Industry Trade Show
Not Confirmed
02-04 June, 2026
Industry Trade Show
Not Confirmed
03-05 June, 2026
Digital content

28 May 2026
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/braeburn-presents-new-data-at-2026-ascp-annual-meeting-demonstrating-opioid-withdrawal-suppression-at-low-buprenorphine-plasma-concentrations-302784648.html

17 Mar 2026
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/nih-funded-randomized-clinical-trial-evaluating-weekly-brixadi-for-opioid-use-disorder-in-pregnancy-and-12-months-postpartum-published-in-jama-internal-medicine-302715253.html

25 Jun 2024
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/braeburn-announces-publication-of-a-post-hoc-analysis-of-data-from-patients-using-fentanyl-treated-with-brixadi-in-a-phase-3-efficacy-and-safety-study-302181924.html

08 Dec 2022
// PRNEWSWIRE
https://www.prnewswire.com/news-releases/fda-accepts-braeburns-new-drug-application-resubmission-for-brixadi-buprenorphine-extended-release-subcutaneous-injection-for-moderate-to-severe-opioid-use-disorder-301698779.html

26 Jun 2021
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/fda-accepts-braeburns-new-drug-application-resubmission-for-brixadi-buprenorphine-extended-release-subcutaneous-injection-for-moderate-to-severe-opioid-use-disorder-301320543.html

15 Jun 2021
// PRNEWSWIRE
https://www.prnewswire.com/news-releases/braeburn-resubmits-new-drug-application-for-brixadi-buprenorphine-extended-release-subcutaneous-injection-for-moderate-to-severe-opioid-use-disorder-301313130.html
ABOUT THIS PAGE